Policy | February 02, 2024
Industry’s reaction to Union Budget 2024-25
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The new campus has been designed as an employee-centred experience and ecosystem zone
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Automated parallel capillary electrophoresis system simplifies protein analysis
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Subscribe To Our Newsletter & Stay Updated
